Beneficial effects of combined treatment with niacin and chromium on the liver of hyperlipemic rats

Biological Trace Element Research

Volumn 101, Issue 3, 2004, Pages 219-229

  Bolkent, Sema ^a   Yanardag, Refiye ^a   Bolkent, Sehnaz ^a   Döger, M Mutluhan ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Cholesterol; Chromium; Hyperlipemia; Liver, niacin; Morphology; Total lipid

Indexed keywords

CHOLESTEROL; CHOLIC ACID; CHROMIUM; LIPID; NICOTINIC ACID; SUNFLOWER OIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CELL REGENERATION; CONTROLLED STUDY; DRUG EFFICACY; ELECTRON MICROSCOPY; FEMALE; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; LIPID DIET; LIPID LIVER LEVEL; LIVER; LIVER CELL; NONHUMAN; RANDOMIZATION; SPECTROPHOTOMETRY; STATISTICAL SIGNIFICANCE;

ANIMALS; ANTILIPEMIC AGENTS; CHOLESTEROL; CHROMIUM; DIETARY FATS; FEMALE; HYPERLIPIDEMIAS; LIPIDS; LIVER; MICE; MICROSCOPY, ELECTRON; NIACIN;

ANIMALIA; HELIANTHUS;

EID: 10044257464     PISSN: 01634984     EISSN: None     Source Type: Journal    
DOI: 10.1385/BTER:101:3:219     Document Type: Article

References (40)

1. R. Altschul, A. Hoffer, and J. D. Stephen, Influence of nicotinic acid on serum cholesterol in man. Arch. Biochem. Biophys. 54, 558-559 (1955).
2. S. R. Summey, Study shows niacin-bound chromium reduces cholesterol, http://www.chiroweb.com/archives/09/24/24.html.
3. J. M. Drood, P. J. Zimetbaum, and W. H. Frishman, Nicotinic acid for the treatment of hyperlipoproteinemia, J. Clin. Pharm. 31, 641-650 (1991).
4. D. M. Capuzzi, J. M. Morgan, O. A. Brusco, and C. M. Intenzo, Niacin dosing: relationship to benefits and adverse effects, Curr. Atherosclerosis Rep. 2, 64-71 (2000).
5. A. C. Goldberg, Clinical trial experience with extended-release niacin (niaspan): dose-escalation study, Am. J. Cardiol. 82, 35U-38U (1998).
6. J. R. DiPalma and W. S. Thayer, Use of niacin as a drug, Annu. Rev. Nutr. 11, 169-187 (1991).
7. J. M. Morgan, D. M. Capuzzi, and J. R. Guyton, A new extended-release niacin (niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients, Am. J. Cardiol. 82, 29U-34U (1998).
8. B. Morris, S. R. Peacey, S. MacNeil, and T. Gray, Enhacement in insulin sensitivity in healthy volunteers following supplementation with chromium picolinate, Med. Biochem. 1, 65-72 (1998).
9. D. Bagchi, S. J. Stohs, B. W. Downs, M. Bagchi, and H. G. Preuss, Cytotoxicity and oxidative mechanisms of different forms of chromium, Toxicology 180, 5-22 (2002).
10. R. A. Anderson, N. A. Bryden, C. M. Evock-Clover, and N. C. Steele, Beneficial effects of chromium on glucose and lipid variables in control and somatotropin-treated pigs are associated with increased tissue chromium and altered tissue copper, iron, and zinc, J. Anim. Sci. 75, 657-661 (1997).
11. H. G. Preuss and R. A. Anderson, Chromium update: examining recent literature 1997-1998, Curr. Opin. Clin. Nutr. Metab. Case 1, 509-512 (1998).
12. M. Simonoff, Chromium deficiency and cardiovascular risk, Cardivasc. Res. 18, 591-596 (1984).
13. Is chromium essential for humans? Nutr. Rev. 46, 17-20 (1988).
14. W. Mertz, Chromium occurance and function in biological systems, Am. Physiol. Soc. 49, 163-239 (1969).
15. A. Goldberg, P. Alagona, Jr., D. M. Capuzzi, et al., Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia, Am. J. Cardiol. 85, 1100-1105 (2000).
16. H. R. Superko and R. M. Krauss, Differential effects of nicotinic acid in subjects with different LDL subclass patterns, Atherosclerosis 95, 69-76 (1992).
17. M. Sakamoto, S. Yanagi, and T. Kamiya, Inhibitory effects of niacin and its analogues on induction of ornithine decarboxylase activity by diethylnitrosamine in rat liver, Biochem. Pharm. 36, 3015-3019 (1987).
18. R. A. Anderson, M. M. Polansky, N. A. Bryden, K. Y. Patterson, C. Veillon, and W. H. Glinsmann, Effects of chromium supplementation on urinary Cr excretion of human subjects and correlation of Cr excretion with selected clinical parameters. J. Nutr. 113, 276-281 (1983).
19. D. M. Bourn, R. S. Gibson, O. B. Martinez, and A. C. MacDonald, The effect of chromium supplementation on serum lipid levels in a selected sample of Canadian postmenopausal women. Biol. Trace Element Res. 9, 197-205 (1986).
20. R. A. Anderson, N. A. Bryden, and M. M. Polansky, Lack of toxicity of chromium cloride and chromium picolinate in rats, J. Am. Coll. Nutr. 16, 273-279 (1997).
21. J. R. Roeback, K. M. Hla, L. E. Chambles, and R. H. Fletcher, Effects of chromium supplementation on serum high-density lipoprotein cholesterol levels in men taking beta-blockers, Ann. Intern. Med. 115, 917-924 (1991).
22. E. B. Kegley, J. W. Spears, and J. H. Eisemann, Performance and glucose metabolism in calves fed a chromium-nicotinic acid complex or chromium chloride, J. Dairy Sci. 80, 1744-1750 (1997).
23. R. A. Anderson, N. A. Bryden, M. M. Polansky, and K. Gautschi, Dietary chromium effects on tissue chromium concentrations and chromium absorbtion in rats, J. Trace Elements Exp. Med. 9, 11-25 (1996).
24. L.L Rikans, D. Arata, and D. C. Cederquist, Fatty livers produced in albino rats by excess niacin in high fat diets. II. Effect of choline supplements, J. Nutr. 85, 107-112 (1965).
25. J. R. Guyton, and D. M. Capuzzi, Treatment of hyperlipidemia with combined niacin-statin regimens, Am. J. Cardiol. 82, 82U-84U (1998).
26. B. G. Brown, J.Bardsley, D. Poulin, et al., Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dL in patients with hyperlipidemia and coronary artery disease, Am. J. Cardiol. 80, 111-115 (1997).
27. L. Cohen and J. Morgan, Effectiveness of individualized long-term therapy with niacin and probucol in reduction of serum cholesterol, J. Fam. Pract. 26, 145-150 (1988).
28. H. G. Preuss, D. Wallerstedt, N. Talpur, et al., Effects of niacin-bound chromium and grapeseed proanthocyanidin extract on the lipid profile of hypercholesterolemic subjects: a pilot study, J. Med. 31, 227-246 (2000).
29. H. K Naito, Cholesterol: review of methods, check sample PTS 85-1, Chicago, American Society of Clinical Pathology, pp. 1-17 (1985).
30. C. S. Frings, T. W. Fendley, R. T. Dunn, and C. A. Queen, Improved determination of serum lipid by sulphophoshovanilin reaction. Clin. Chem. 18, 673-674 (1972).
31. J. L. Hintze, Copright C. 865, East 400. North Kaysville, Utah, 84,037 (801), 546-0445 (1986).
32. R. G. Lefavi, G. D. Wilson, R. E. Keith, et al., Lipid-lowering effect of dietary chromium (III)-nicotinic acid complex in male athletes, Nutr. Res. 13, 239-249 (1993).
33. M. D. Cohen, B. Kargacin, C. B. Klein, and M. Costa, Mechanisms of chromium carcinogenicity and toxicity, Crit. Rev. Toxicol. 23, 255-281 (1993).
34. M. Urberg, J. Benyi, and R. John, Hypocholesterolemic effects of nicotinic acid and chromium supplementation, J. Fam. Pract. 27, 603-606 (1988).
35. M. M. Wang, E. A. Fox, B. J. Stoecker, C. E. Menendez, and S. B. Chan, Serum cholesterol of adults supplemented with Brewer's yeast or chromium chloride, Nutr Res. 9, 989-998 (1989).
36. H. A. Schroeder, W. H. Vinton, and J. J. Balasssa, Effect of chromium, cadmium and lead on serum cholesterol of rats. Proc. Soc. Exp. Biol. Med. 109, 859-860 (1962).
37. G. L. Curran, Effect of certain transition group elements on hepatic synthesis of cholesterol in the rats. J. Biol. Chem. 270, 765-770 (1954).
38. B. Angelin, M. Eriksson, and K. Einarsson, Combined treatment with cholestyramine and nicotinic acid in heterozygous familial hypercholesterolaemia: effects on biliary lipid composition, Eur. J. Clin. Invest. 16, 391-396 (1986).
39. T. Sakai, S. Vaijinath, S. Kamanna, and M. L. Kashyap, Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfruction of HDL, in patients with low HDL cholesterol, Arteriosclerosis Throm. Vasc. Biol. 21, 1783-1797 (2001).
40. E. G. Offenbacher and F. X. Pi-Sunyer, Beneficial effect of chromium-rich yeast on glucose tolerance and blood lipids in elderly subjects, Diabetes 29, 919-925 (1980).